Table 2.

Demographic of subjects

	Placebo	Active treatment
Patients (n)	9	14
Sex (% females)	77.8%	50.0%
Age at baseline, years	60.1 (39.3–64.8)	55.2 (42.0–66.0)
Disease duration at baseline, years	26.0 (10.4–43.6)	24.4 (16.5–38.5)
Total duration of follow‐up, months	30.0 (18.0–36.0)	24.0 (13.5–36.0)
EDSS at baseline	6.5 (5.0–6.5)	6.5 (2.5–7.0)
IgG index at baseline	0.71 (0.46–1.8)	0.86 (0.40–2.36)
OCB positivity at baseline	88.9% (8/9)	100% (14/14)
CEL positivity (Mo −12/Mo 0)	25.0%/11.1%	14.3%/0%

Data are median (range), unless otherwise stated.

EDSS, expanded disability status scale; OCB, oligoclonal bands; CEL, contrast‐enhancing lesion in MRI; Mo, month.